Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...
January 7, 2020
April 17, 2018
Click here to read the press release.